28 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
Transactions, and Director Independence 91 Item 14. Principal Accounting Fees and Services 91 PART IV Item 15. Exhibits, Financial Statement Schedules … , whether a reverse payment is justified depends upon its size, scale in relation to the patentee’s anticipated future litigation costs, and independence
ARS
v8ykng
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
fjmkyw
18 Apr 23
Preliminary proxy
7:59am
424B4
pp1y90ctba
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
6lqai
19 May 21
Draft registration statement
12:00am